INSTITUTO DE SALUD CARLOS III [ ISCIII ]

CALLE SINESIO DELGADO 4-6 28029 MADRID - Spain

Involved in the following projects during the 3rd programme

3rd Health Programme (2014-2020)
Information for Action [InfAct]
InfAct (Information for Action) is a JA on health information (HI). HI is essential to build up country specific and cross-country knowledge. HI is the basis to inform national health policies, to ste...
InfAct (Information for Action) is a JA on health information (HI). HI is essential to build up country specific and cross-country knowledge. HI is the basis to inform national health policies, to steer population health investment decisions, to assess the effectiveness of different approaches to enhance population health through promotion, prevention, treatments and care. Timely, up-to-date HI is also vital in framing EU wide programs and policies.

The major outcome expected of the JA is a sustainable solid infrastructure on EU HI through improving the availability of comparable, robust and policy-relevant health status data and health system performance information. Through country collaboration, the JA streamlines HI activities, reduces the data collection burden and works for a sustainable and robust data collection in Europe that facilitates and supports country knowledge, health research and policy making.

The JA gives attention to:

• develop the business case and roadmap for implementation of the European Research Infrastructure Consortium on Health Information for Research and Evidence-based Policy
o governance structures,
o national HI consortia and domain specific HI research networks
• assess HI systems (HIS) in MS and regions
• develop a roadmap for training in HI with the objective to tackle HI inequality through Europe
• standardize HI instruments, tools and methods
• strengthen the HI efficiency for public health policy through new ways of using health and non-health data sources
• enhance the introduction of the interoperability of health data sources
• enhance the translation of HI into public policy

The JA watches for the sustainability of all actions taken by the JA. Coordination, dialogue and interaction with the Commission Expert Groups on HI and on HSPA, Eurostat, DG Research and other relevant DGs, international organization (WHO, OECD) reinforce further the sustainability of the JAs’ work and outcomes.

Start date: 01/03/2018 - End date: 31/05/2021

Call: Joint Actions 2017
Topic: Joint Action on Health Information towards a sustainable EU health information system that supports country knowledge, health research and policy-making.
3rd Health Programme (2014-2020)
Strengthened International HeAlth Regulations and Preparedness in the EU - Joint Action [SHARP JA]
The SHARP Joint Action will strengthen implementation of Decision 1082/2013/EU, supporting the EU level preparedness and responses to health threats and the implementation of the International Health ...
The SHARP Joint Action will strengthen implementation of Decision 1082/2013/EU, supporting the EU level preparedness and responses to health threats and the implementation of the International Health Regulations (2005). The Joint Action implements actions mentioned in Annex 1 of the Annual Work plan 2018 of the EU Health Programme 2014-2020.
Through the Joint Action, the member and partner states and the Unions common ability to prevent, detect and respond to biological outbreaks, chemical contamination and environmental and unknown threats to human health will be strengthened. Special efforts will be employed to fill gaps that have been or will be identified in priority countries (countries that have biggest gaps in the capacity required for full IHR capability). The Joint action consists of 10 Work Packages, covering core public health capacities according to the IHR (2005). In addition to a coordination function, these will cover areas such as Communication, Evaluation, Sustainability, IHR core capacity, Preparedness, Laboratories, Training and exercises, Chemical threats and Clinical management.
SHARP will also collaborate with several other Joint Actions, specifically the “Healthy Gateways” that addresses Points of Entry, the Joint Action on Vaccination (EU-JAV) and the Joint Action on Antimicrobial Resistance (EU-JAMRAI).
The partnership of the joint action consists of 26 Associated Partners and 33 Affiliated Entities, which all will receive Commission co-funding. In addition there are 9 Collaborating Partners that will self-fund all activities that they participate in. Totally 30 countries (24 EU members, 3 EEA/EFTA members and 3 European neighborhood countries) participate in the Joint Action. The SHARP JA will liaise with and collaborate with the ECDC, the WHO EURO regional office and the WHO Health Emergency and IHR unit in Lyon, and IANPHI in relevant activities. Special emphasis will be made to avoid duplication of work for the member states.

Start date: 01/04/2019 - End date: 31/03/2023

Call: Joint Actions 2018
Topic: Joint Action to strengthen preparedness including laboratories in the EU against serious cross-border threats to health and support the implementation of International Health Regula...
Topic: Joint Action to strengthen preparedness including laboratories in the EU against serious cross-border threats to health and support the implementation of International Health Regulations (IHR)
3rd Health Programme (2014-2020)
BRidging Information and Data Generation for Evidence-based Health Policy and Research [BRIDGE Health]
BRIDGE Health (BRidging Information and Data Generation for Evidence-based Health Policy and Research) aims to create European health information (EU-HI) and data generation networks covering major EU...
BRIDGE Health (BRidging Information and Data Generation for Evidence-based Health Policy and Research) aims to create European health information (EU-HI) and data generation networks covering major EU health policy areas. The network uses comprehensive experience and assures a knowledge transfer from past health and research frameworks.

The aim is to work towards a comprehensive, integrated and sustainable EU-HI supporting evidence-based health policy and research for the EU and Member States by providing blueprints and/or concepts of building blocks for a future EU-HI research infrastructure consortium (ERIC-HI).

The project bridges key EU projects in domains of population and health system monitoring and indicator development, health examination surveys, environment and health, population injury and disease registries, clinical and administrative health data collection systems and methods of health system monitoring and evaluation.

The project aims to:
1) enhance the transferability of health information and data for policy and improve the utility and use of data and indicators for stakeholders in policy making, public health surveillance and health care;
2) reduce health information inequality within the EU and within MS;
3) develop a blueprint for a sustainable and integrated EU Health information system by developing common methods for a) standardising the collection and exchange of health information within and between domains, between MS, including e-health platforms; b) ensuring data quality, including procedures for internal and external validation of health indicators; c) undertaking priority setting exercises for health information, d) addressing ethical and legal issues associated with the collection and use of health data within MS and the EU.

Coordination, dialogue and interaction with DG-SANCO, the Expert Group on Health Information, Eurostat, DG Research and other DGs ensure the sustainability of the work and bridges to a future ERIC-HI.
Start date: 01/05/2015 - End date: 31/10/2017
Call: Call for Proposals for Projects 2014
Topic: Health monitoring and reporting system
3rd Health Programme (2014-2020)
Efficient response to highly dangerous and emerging pathogens at EU level [EMERGE]
The human population is confronted with emerging and re-emerging infectious pathogens that can cause serious cross-border outbreaks. A recent example is the Ebola outbreak requiring strong diagnostic,...
The human population is confronted with emerging and re-emerging infectious pathogens that can cause serious cross-border outbreaks. A recent example is the Ebola outbreak requiring strong diagnostic, clinical, and public health measures in Europe and abroad in order to get this incident under control. The JA EMERGE is in compliance with the European policy (Decision No 1082/2013/EU) where the need for an efficient, rapid and coordinated response to high threat pathogens is defined. The JA EMERGE comprises a European network with more then 40 diagnostic laboratories focused on risk group 3 bacteria and risk groups 3 and 4 viruses. It will act in a so-called inter-epidemic mode (IEM) which can be activated and switched into an outbreak response mode (ORM) on request by the Health Security Committee in order to direct all activities to the outbreak management. A number of other laboratory networks, institutions and agencies are contributing to the management of cross-border infectious outbreaks. EMERGE will provide a platform for establishment and consolidation of a common, coordinated and effective response to infectious disease outbreaks at EU level and abroad (WP4). State of the art and new diagnostic methods for high threat pathogens, including in-house and commercial kits, will be evaluated for their applicability and recommended in outbreak situations when suitable (WP5). External quality assurance exercises will ensure best approaches for laboratory responsiveness in outbreak situations (WP6). These activities must be supported by an appropriate training to share best practices of diagnostics and bio-risk management (WP7). In conclusion, the general objective will be to ensure efficient response to serious emergent and re-emergent cross-border events by reinforcing the existing EU network of BSL 3 and BSL 4 laboratories which are already active in the field of identification of dangerous bacterial and viral human pathogens.
Start date: 01/06/2015 - End date: 31/03/2019

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: Pathogens Joint Action
3rd Health Programme (2014-2020)
European Network for Health Technology Assessment (EUnetHTA) - Joint Action 3 [EUnetHTA JA3]
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and...
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and health technologies and ensure re-use in regional and national HTA reports and activities, in order notably to avoid duplication of assessments. An overarching objective is to develop a general strategy, principles and proposal for a scientific and technical mechanism of permanent sustainable European Collaboration on HTA in the light of the Directive on CBHC. During the JA3 the collaborative production of structured HTA core information, including rapid HTAs will be structurally implemented and the methodologies and production related information and communication technology infrastructure will be finalised as to stand alone from 2020 onwards. EUnetHTA JA3 will also aim to increase the alignment between HTA reports used for reimbursement decisions and clinical practice guidelines that are used by physicians in daily practice. Additionally, EUnetHTA JA3 will also support more alignment of different processes in the lifecycle of health technologies. For instance, processes on market authorization and HTA of pharmaceuticals could be organised in a more closely aligned fashion which may lead to a timelier and more efficient process promoting earlier patient access to products that have a real added value. EUnetHTA JA3 will also contribute to the discussion on the assessment of the effectiveness and safety of new medical devices as is currently taken place as part of the debate on new European legislation for medical devices. Finally, all these outcomes will contribute to the dissemination of health information and knowledge, thus improving policy-and decision-making in the health systems, which turns into protection of citizens against unsafe or ineffective technologies and improves access to high value health technologies. Ultimately this contributes to imTo be developed
Start date: 01/06/2016 - End date: 31/05/2021

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Health Technology Assessment cooperation
3rd Health Programme (2014-2020)
CHRODIS-PLUS: Implementing good practices for chronic diseases [CHRODIS-PLUS]
Europe is paying a heavy price for chronic diseases (CD): it has been estimated that CD cost EU economies 115 billion € or 0.8% of GDP annually; and this figure does not include the additional loss ...
Europe is paying a heavy price for chronic diseases (CD): it has been estimated that CD cost EU economies 115 billion € or 0.8% of GDP annually; and this figure does not include the additional loss in terms of lower employment rates and productivity of people living with chronic health problems. However, the aspiration is a health-promoting Europe, free of preventable CD, premature death and avoidable disability could be possible. Initiatives on CD should build on four cornerstones: health promotion and primary prevention as a way to reduce the burden of CD; patient empowerment; tackling functional decline and quality of life as the main consequences of CD, and making health systems sustainable and responsive to the aging of our populations associated with the epidemiological transition (an increase in incidence of CD and extended life expectancy) whose consequence is an increasing prevalence of CD. In this Joint Action, CHRODIS-PLUS, our goal is to support Member States through cross-national initiatives identified in JA-CHRODIS to reduce the burden of CD, while assuring health systems sustainability and responsiveness. CHRODIS-PLUS aims to promote the implementation of policies and practices with demonstrated success in each of the four cornerstones mentioned, in closely monitored implementation experiences that can be validated before scaling them up. For this, a total of 42 beneficiaries representing 20 European countries will collaborate to implement pilots and generate practical lessons that could contribute to the uptake and use of CHRODIS-PLUS results. Practices to be implemented will be based on the collection of policies, strategies and interventions that started in JA-CHRODIS and in its outputs such as the Integrated Multimorbidity Care Model or the Recommendations for Diabetes Quality criteria or national plans. During the 36-month life CHRODIS-PLUS will disseminate its activities and monitor and evaluate them to verify the progress and impact of the action. CHRODIS-PLUS will look for synergies with international/regional/local policy initiatives in CD. CHRODIS-PLUS will count on the Governing Board of representatives from European Ministries of Health, key to CHRODIS-PLUS development and sustainability, an Executive Board and a General Assembly where all associated partners will gather. A proposal for the EU added value of cross-country collaboration in the field of CD and the sustainability of the results from JA-CHRODIS and CHRODIS-PLUS beyond 2020, when this project ends, will be approved.
Start date: 01/09/2017 - End date: 30/11/2020

Call: Joint Actions 2016
Topic: Action on chronic diseases
3rd Health Programme (2014-2020)
European Joint Action on antimicrobial resistance and associated infections [EU-JAMRAI]
Antimicrobial resistance (AMR) is a serious public health threat that is gaining swift ground. The increase of multi-resistant bacteria associated to the lack of new antibiotics represents a threat to...
Antimicrobial resistance (AMR) is a serious public health threat that is gaining swift ground. The increase of multi-resistant bacteria associated to the lack of new antibiotics represents a threat to global health. Some patients are faced with no therapeutic solutions as some bacteria resist to all antibiotics. Moreover, “old” antibiotics and to some extent more “recent” ones are gradually removed from the market because they are not economically sustainable, albeit being still possibly efficient. The issue of antimicrobial resistance is a real challenge that decision-makers are well aware of and has gained a high priority among public health challenges.
A closely related challenge is the issue of Healthcare Associated Infections that shall not be considered separately. In fact, infection prevention and control strategies should go hand in hand with i) prudent use of antibiotics ii) appropriate tools for monitoring and surveillance and iii) accurate diagnostic tests to decide on the right therapy.
The various national, European and international initiatives that have emerged over the last decade have shown a great commitment to actively tackle these issues.It is essential that all actors in the field of AMR join forces so as to avoid duplication of efforts and ensure greater coherence. Moreover, it is essential that the strategies adopted extend beyond the sole human health domain and bring a global One Health response.
The overall objective of the AMR-HCAI JA is to ensure that policies for control of AMR and HCAI are adopted and implemented across EU MS in a coordinated way, ensuring national specificities are accounted for, in line with the ECDC and WHO guidelines and recommendations, and in conjunction with other European initiatives.This will be made possible by bringing together different networks of policy makers, experts and organizations on AMR and HCAI working in different European and International initiatives and projects relevant for policy decision.
Start date: 01/09/2017 - End date: 28/02/2021

Call: Joint Actions 2016
Topic: Antimicrobial resistance and Health Care Associated Infections
3rd Health Programme (2014-2020)
Joint Action on HIV and Co-infection Prevention and Harm Reduction [HA-REACT]
The Joint Action proposal on “HIV and Co-infection Prevention and Harm Reduction” (HA-REACT) addresses existing gaps in the prevention of HIV and other co-infections (especially tuberculosis and h...
The Joint Action proposal on “HIV and Co-infection Prevention and Harm Reduction” (HA-REACT) addresses existing gaps in the prevention of HIV and other co-infections (especially tuberculosis and hepatitis) in priority areas of the EU. Despite huge advances in treatment and care and successful implementation of evidence-based preventive interventions in many EU member states, these infections are still not controlled among certain population groups and regions. The HA-REACT Joint action (JA) directly addresses the Communication from the Commission [COM(2009)569] on “Combating HIV/AIDS in the European Union and neighbouring countries, 2009 -2013” and relevant actions laid out in the associated [SWD(2014)106] action plan extension 2014-2016. The project takes a practical rather than a theoretical or purely guiding approach. It will implement concerted, multi-country, and multi-actor actions, strengthening evidence-based practices in the focus countries, where the situation and needs are particularly challenging. Focused action for greater impact is the leading principle of this proposal. The HA-REACT will focus on pragmatic actions targeting the most vulnerable populations, i.e. people who inject drugs (PWID). The focus countries for the JA were selected according to an objective and transparent selection criteria, developed by the ECDC and the EMCDDA in which the countries were ranked according to their epidemic situation and coverage of preventive measures. In addition to work packages of Coordination, Dissemination and Evaluation, HA-REACT actions are organized into five core work packages: Testing and linkage to care, Scaling up harm reduction, Harm reduction and continuity of care in prisons, Integrated care, Sustainability and long-term funding.
Start date: 01/10/2015 - End date: 31/01/2019

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: HIV Joint Action
3rd Health Programme (2014-2020)
JOINT ACTION ON INCREASING THE CAPACITY OF NATIONAL FOCAL POINTS (NFP) [NFP4Health]
National Focal Points form an advisory system to participants that operate locally, and with the capacity of allowing equitable
participation in the EU Health Programme across countries.

To provide h...
National Focal Points form an advisory system to participants that operate locally, and with the capacity of allowing equitable
participation in the EU Health Programme across countries.

To provide high quality services to potential applicants and project participants, NFPs should have a common sound knowledge of the rules and procedures of the EU Health Programme. Besides, they should be aware of other available initiatives at both national/regional and EU level that may complement or fit better the needs of national health communities. This last includes leading stakeholders to the right person or organisation, so they can be duly informed.

NFP4Health will contribute to create an innovative, sustainable and coherent network of NFPs that will increase the capacity of the Member States to design and create sustainable implementation actions that will boost the achievement of health objectives for the period
2021-2027. The network will create the best framework to contribute to the growth of innovative, efficient and sustainable health systems.
The main goal of increasing capacities of National Focal Points (NFPs) Joint Action is to create and maintain an innovative ecosystem to facilitate and support that European countries can achieve health objectives priorities established for the period 2021-2027. By developing and strengthening the NFPs capacities of European Countries, the Joint Action aims to provide quality access to the new EU4HEALTH Programme and to assure the complementarity with other regional, national and EU policies, funds and programmes. This action will allow maximizing efforts to leverage all available health funding, to guarantee the accessibility and sustainability of healthcare systems.

To really achieve the change it is necessary to help Member States to build their capacity to design sustainable implementation actions,
irrespective of the source of funding being EU4Health or other EU funding instruments.
Start date: 01/10/2021 - End date: 30/09/2024

Call: Direct Grants for Joint Actions with Member State's Competent Authorities under the Annual Work Programme 2020 of the 3HP
Topic: • Joint Action on Increasing the capacity of national focal points (NFPs) to provide guidance, information and assistance to national applicants on the implementation of the ESF+ ...
Topic: • Joint Action on Increasing the capacity of national focal points (NFPs) to provide guidance, information and assistance to national applicants on the implementation of the ESF+ health strand